SEC Filing Summary: ChromaDex Corp. (8-K)
Business Context and Reporting Period
This Form 8-K was filed by ChromaDex Corp. on January 3, 2014, reporting events occurring on December 30, 2013. The filing details the entry into a Material Definitive Agreement regarding the assignment of a senior convertible secured note issued by Neutrisci International Inc. to Alpha Capital Anstalt.
Key Financial Metrics and Transaction Details
- Purchase Price: $1,250,000 paid by the Assignee for the assignment of the Note and related security interests.
- Note Outstanding Balance: $2,275,000 of a $2,500,000 senior convertible secured note issued by Neutrisci.
- Transaction Fees:
- Legal fees paid to Assignee: $7,500.
- Placement agent cash fee to Palladium Capital Advisors: $100,000 (8% of Purchase Price).
- Placement agent cash bonus to Palladium Capital Advisors: $50,000.
- Contingent Equity Consideration:
- Transfer of Neutrisci preferred stock valued at $500,000 to the Assignee upon Neutrisci's common stock listing.
- Transfer of Neutrisci preferred stock valued at $50,000 to Palladium Capital Advisors upon Neutrisci's common stock listing.
Note: This filing does not provide consolidated revenue, profit, cash flow, margins, or liquidity metrics for ChromaDex Corp. or Neutrisci International Inc.
Material Changes and Unusual Items
The primary material change is the transfer of a significant financial asset (the Note) and associated security interests from ChromaDex to Alpha Capital Anstalt. This transaction reduces ChromaDex's exposure to the Neutrisci debt instrument in exchange for immediate cash proceeds and contingent equity rights.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on future operations, or specific risk factors beyond the standard disclaimer that the summary is qualified by the full Assignment Agreement. The transaction is contingent on future actions by Neutrisci regarding the listing of its common stock for the equity components to vest.
Investor Verification Checklist
- Verify the current status of the $2,275,000 outstanding note and whether the assignment was fully consummated.
- Confirm the cash proceeds actually received by ChromaDex after deducting the $157,500 in fees ($7,500 legal + $100,000 fee + $50,000 bonus).
- Monitor Neutrisci International Inc.'s progress toward listing its common stock on an exchange to determine if the contingent preferred stock transfers will occur.
- Review the full Assignment and Escrow Agreement (Exhibit 10.1) for covenants or restrictions not detailed in this summary.